Integra Lifesciences Holdings Corp [IART] stock prices are up 1.94% to $17.88 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IART shares have gain 4.20% over the last week, with a monthly amount drifted -15.14%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Integra Lifesciences Holdings Corp [NASDAQ: IART] stock has seen the most recent analyst activity on July 30, 2024, when Citigroup downgraded its rating to a Sell and also revised its price target to $23 from $30. Previously, BTIG Research downgraded its rating to Sell on July 30, 2024, and kept the price target unchanged to $22. On May 07, 2024, downgrade downgraded it’s rating to Equal Weight and revised its price target to $25 on the stock. Oppenheimer downgraded its rating to a Perform. Citigroup upgraded its rating to a Neutral but $38 remained the price target by the analyst firm on April 03, 2024. Wells Fargo upgraded its rating to Overweight for this stock on December 05, 2023, and upped its price target to $49. In a note dated November 14, 2023, CL King initiated an Buy rating and provided a target price of $50 on this stock.
The stock price of Integra Lifesciences Holdings Corp [IART] has been fluctuating between $16.96 and $45.42 over the past year. Currently, Wall Street analysts expect the stock to reach $43.25 within the next 12 months. Integra Lifesciences Holdings Corp [NASDAQ: IART] shares were valued at $17.88 at the most recent close of the market. An investor can expect a potential return of 141.89% based on the average IART price forecast.
Analyzing the IART fundamentals
The Integra Lifesciences Holdings Corp [NASDAQ:IART] reported sales of 1.57B for trailing twelve months, representing a surge of 9.68%. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.01 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.53 points at the first support level, and at 17.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.23, and for the 2nd resistance point, it is at 18.57.
Ratios To Look Out For
It’s worth pointing out that Integra Lifesciences Holdings Corp [NASDAQ:IART]’s Current Ratio is 3.39. In addition, the Quick Ratio stands at 2.10 and the Cash Ratio stands at 0.66. Considering the valuation of this stock, the price to sales ratio is 0.89, the price to book ratio is 0.90 and price to earnings (TTM) ratio is 60.59.
Transactions by insiders
Recent insider trading involved Mosebrook Jeffrey, SVP, Fin & Princ Acct Officer, that happened on Aug 19 ’24 when 1191.0 shares were sold. Exec. Chairman of the Board, ESSIG STUART completed a deal on May 23 ’24 to buy 52641.0 shares. Meanwhile, Director HILL BARBARA B bought 36350.0 shares on May 21 ’24.
